Article: Third Time's Not A Charm Encysive Tanks On Third PAH Approvable Letter For Thelin.

Byline: Trista Morrison, Staff Writer

Shares of Encysive Pharmaceuticals Inc. fell 43.4 percent after the Houston-based company received its third approvable letter for Thelin (sitaxsentan sodium) 100 mg tablets in the treatment of pulmonary arterial hypertension (PAH).

President and CEO Bruce Given said in a Monday morning conference call that the company is "moving to formal dispute resolution" with the FDA. At issue, according to Given, is whether the special protocol assessment (SPA) agreed upon by both parties for a Phase III trial called STRIDE-2 is binding.

The new drug application filing for Thelin was based on data from two randomized, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!